7月16日，德康医疗盘中上涨5.6%，报77.52美元/股，成交额5445.62万美元。
消息面上，Truist当日将德康医疗目标价从80美元上调至87美元，维持买入评级。此外，公司G7 15天连续血糖监测系统于7月14日获得加拿大卫生部授权批准，适用于18岁及以上成年糖尿病患者，为加拿大获批的最长续航CGM设备，佩戴时间可达15.5天。当前分析师平均目标价约86美元。同日医疗保健设备板块整体走强，雅培涨12.37%、史赛克涨5.7%、波士顿科学涨5.24%，板块联动亦提供支撑。公司定于7月30日发布二季度财报，市场预期EPS为0.61美元。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.